AI
KTTA icon

AdvisorShares Investments’s Pasithea Therapeutics KTTA Stock Holding History

AdvisorShares Investments’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$483K Buy
937,550
+600,042
+178% +$413K 0.06% 185
2026
Q1 		$250K Buy
337,508
+32,787
+11% +$27.4K 0.05% 225
2025
Q4 		$393K Buy
304,721
+47,025
+18% +$41.3K 0.07% 201
2025
Q3 		$186K Buy
257,696
+64,149
+33% +$46.9K 0.03% 226
2025
Q2 		$140K Buy
193,547
+140,000
+261% +$153K 0.03% 234
2025
Q1 		$66.4K Buy
+53,547
New +$95.1K 0.01% 259

Other funds holding KTTA

PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
HC
Hurley Capital New York $193M AUM 25.58% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

AdvisorShares Investments's KTTA Position: Q2 2026 in Review

AdvisorShares Investments increased its Pasithea Therapeutics (KTTA) stake by 178% in Q2 2026, buying an estimated $413K and bringing the position to 937,550 shares worth $483K. The position accounts for 0.06% of the portfolio, ranked #185.

AdvisorShares Investments first reported a position in KTTA in Q1 2025 and has held it in 6 quarters since. 6 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • AdvisorShares Investments held 937,550 shares of Pasithea Therapeutics worth $483K as of Q2 2026.
  • AdvisorShares Investments bought 600,042 Pasithea Therapeutics shares in Q2 2026, an estimated $413K.
  • Pasithea Therapeutics made up 0.06% of AdvisorShares Investments's portfolio in Q2 2026, its #185 holding.
  • AdvisorShares Investments first reported a position in Pasithea Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 6 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on AdvisorShares Investments's 13F filing for Q2 2026, filed 11 Aug 2026.